Adjuvants and autoimmunity

Lupus

Volumn 18, Issue 13, 2009, Pages 1217-1225

  Israeli, E ^a   Agmon Levin, N ^a   Blank, M ^a   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adjuvant disease; Adjuvants; Alum; Autoimmune diseases; Autoimmunity; Gulf War syndrome (GWS); Immunity; Inflammasome; Macrophgic myofaciitis; Mechanism; Mineral oil; Pristane; Silicone; Toll like receptors (TLR); Uric acid; Vaccines

Indexed keywords

ADJUVANT; ALUMINUM SALT; FREUND ADJUVANT; TOLL LIKE RECEPTOR; VIROSOME;

ADAPTIVE IMMUNITY; ADJUVANT DISEASE; ARTICLE; AUTOIMMUNITY; CELLULAR IMMUNITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; PRIORITY JOURNAL; VACCINATION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNITY; HUMANS; IMMUNITY, INNATE; PERSIAN GULF SYNDROME; TOLL-LIKE RECEPTORS;

EID: 71049139322     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309345724     Document Type: Article

References (50)

1. Holzer BR, Hatz C., Schmidt-Sissolak D., Gluck R., Althaus B., Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: A randomized controlled trial. Vaccine 1996; 14: 982-986.
2. Gluck R. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine 1999; 17: 1782-1787.
3. Riedl K., Riedl R., von Gabain A., Nagy E., Lingnau K. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 2008; 26: 3461-3468.
4. Pichichero M. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin 2008; 4: 262-270.
5. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355: 1445-1455.
6. Alexeev V., Mucci T., Igoucheva O. Immunotherapeutic strategies for the treatment of malignant melanoma. G Ital Dermatol Venereol 2008; 143: 139-149.
7. Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? Nature Clin Prac 2009; 6: 70-71.
8. Ghochikyan AMM, Petrushina I., Movsesyan N., Karapetyan A., Cribbs DH, Agadjanyan MG Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine 2006; 24: 2275-2282.
9. Ulrich Jtmk. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995; 6: 495-524.
10. Bahr Gmcl. Immunological activities of muramyl peptides. Fed Proc 1986; 45: 2541-2544.
11. Krieg AM, Yi AK, Matson S., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
12. Lipford GB, Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. Eur J Immunol 1997; 27: 2340-2344.
13. Millan Clwr, Krieg AM, Siegrist CA, Davis HL CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 1998; 95: 15553-15558.
14. Zimmerman SEO, Hausmann S., Lipford GB, Rocken W., Wagner H., Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998; 160: 3627-3630.
15. Schijns VE Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000; 12: 456-463.
16. Bousso P., Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nature Immunol 2003; 4: 579-585.
17. Mempel TR, Henrickson SE, Von Andrian UH T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004; 427: 154-159.
18. Kashiwakura J., Yokoi H., Saito H., Okayama Y. T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: Comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol 2004; 173: 5247-5257.
19. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430: 257-263.
20. Poltorak A., He X., Smirnova I., et al. Defective LPS signaling in C3H/ HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998; 282: 2085-8.
21. Takeda K., Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
22. Shizuo A. Toll-like receptor signaling. J Biol Chem 2003; 278: 38105-38108.
23. Moreira LO, Smith AM, DeFreitas AA, Qualls JE, El Kasmi KC, Murray PJ Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2. Vaccine 2008; 26: 5808-5813.
24. Mosca F., Tritto E., Muzzi A., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 2008; 105: 10501-10506.
25. Iglesias ETR, Carazana Y., Lobaina Y., et al. Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV-1. Immunol Cell Biol 2006; 84: 174-183.
26. Gavin AL, Hoebe K., Duong B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006; 314: 1936-1938.
27. Eisenbarth SC, Colegio OR, O'Connor W., Sutterwala FS, Flavell RA Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453: 1122-1126.
28. Kool M., Soullie T., van Nimwegen M., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205: 869-882.
29. Kool M., Petrilli V., De Smedt T., et al. Cutting edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008; 181: 3755-3759.
30. Molina V., Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005; 38: 235-245.
31. McAnally JL, Xu L., Villain M., Blalock JE The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis. Exp Biol Med 2001; 226: 307-311.
32. Agmon-Levin N., Shoenfeld Y. Chronic fatigue syndrome with autoantibodies - the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 2008; 8: 52-55.
33. Di Benedetto G., Pierangeli M., Scalise A., Bertani A. Paraffin oil injection in the body: An obsolete and destructive procedure. Ann Plast Surg 2002; 49: 391-396.
34. Anderson PN, Potter M. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature 1969; 222: 994-995.
35. Cannon GW, Woods ML, Clayton F., Griffiths MM Induction of arthritis in DA rats by incomplete Freund's adjuvant. J Rheumatol 1993; 20: 7-11.
36. Carlson BC, Jansson AM, Larsson A., Bucht A., Lorentzen JC The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000; 156: 2057-2065.
37. Satoh M., Kumar A., Kanwar YS, Reeves WH Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA 1995; 92: 10934-10938.
38. Satoh M., Reeves WH Induction of lupus-associated autoantibodies in BALB/ c mice by intraperitoneal injection of pristane. J Exp Med 1994; 180: 2341-2346.
39. Kuroda Y., Akaogi J., Nacionales DC, et al. Distinctive patterns of autoimmune response induced by different types of mineral oil. Toxicol Sci 2004; 78: 222-228.
40. Kuroda Y., Nacionales DC, Akaogi J., Reeves WH, Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 2004; 58: 325-337.
41. Spiera RF, Gibofsky A., Spiera H. Silicone gel filled breast implants and connective tissue disease: An overview. J Rheumatol 1994; 21: 239-245.
42. Janowsky EC, Kupper LL, Hulka BS Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med 2000; 342: 781-790.
43. Vasey FB, Zarabadi SA, Seleznick M., Ricca L. Where there's smoke there's fire: The silicone breast implant controversy continues to flicker: A new disease that needs to be defined. J Rheumatol 2003; 30: 2092-2094.
44. Gherardi RK Lessons from macrophagic myofasciitis: Towards definition of a vaccine adjuvant-related syndrome. Rev Neurolog 2003; 159: 162-164.
45. Asa PB, Cao Y., Garry RF Antibodies to squalene in Gulf War syndrome. Exp Molec Pathol 2000; 68: 55-64.
46. Petrovsky N., Aguilar JC Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 2004; 82: 488-496.
47. Reed SG, Bertholet S., Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30: 23-32.
48. Rose NR The adjuvant effect in infection and autoimmunity. Clin Rev Allergy Immunol 2008; 34: 279-282.
49. Carlson BC, Jansson AM, Larsson A., Bucht A., Lorentzen JC The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000; 156: 2057-2065.
50. Hennekens CH, Lee IM, Cook NR, et al. Self-reported breast implants and connective-tissue diseases in female health professionals. A retrospective cohort study. J Am Med Assoc 1996; 275: 616-621.